sabcs 2010 intro

Article

Dear Colleague: Targeted therapies and personalized medicine have become two major buzzwords in cancer care. But as breast cancer specialists, we have incorporated both into our practice for some time. For instance, tamoxifen is a targeted therapy, although we didn’t necessarily call it by that name. When it comes to personalized medicine, one of our goals has been to find better prognostic and predictive factors: Can we identify which patients will benefit from a specific therapy? Can we pinpoint those patients who can safely avoid chemotherapy? The 2010 San Antonio Breast Cancer Symposium (SABCS) offers all breast cancer specialists the chance to explore the wealth of data that we have amassed over the years. Join Oncology NEWS International for onsite reports from SABCS 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way breast cancer is managed and treated. Check back here daily during the meeting and watch your inbox for our exciting reports from the SABCS 2010.

San Antonio Breast Cancer Symposium

 

Dear Colleague:

Targeted therapies and personalized medicine have become two major buzzwords in cancer care. But as breast cancer specialists, we have incorporated both into our practice for some time. For instance, tamoxifen is a targeted therapy, although we didn’t necessarily call it by that name. When it comes to personalized medicine, one of our goals has been to find better prognostic and predictive factors: Can we identify which patients will benefit from a specific therapy? Can we pinpoint those patients who can safely avoid chemotherapy?

The 2010 San Antonio Breast Cancer Symposium (SABCS) offers all breast cancer specialists the chance to explore the wealth of data that we have amassed over the years. Join Oncology NEWS International for onsite reports from SABCS 2010 as we bring you a bird’s eye view of the research, trials, scientific advances, and controversies that are changing the way breast cancer is managed and treated.

Check back here daily during the meeting and watch your inbox for our exciting reports from the SABCS 2010.

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content